Lonza Appoints Wolfgang Wienand as New Chief Executive Officer - Seite 2

Christoph Mäder, Lead Independent Director and Vice-Chairman, Lonza, added: “Wolfgang is a high-caliber leader with outstanding CDMO experience. He will be a great asset to our business. As Wolfgang takes the role of CEO, Albert Baehny will step down from his ad interim CEO position. I would like to take this chance to thank Albert for his extraordinary dedication and leadership in recent months. As Albert also plans to step down from the Board of Directors in May, I would also like to take this chance to thank him for the critical role he has played in the growth and transformation of our business during his time as Chairman.”

Wolfgang Wienand, incoming Chief Executive Officer, Lonza, commented: “I am very much looking forward to joining Lonza and leading the company into a strong future. Lonza is world class, as is the scientific, technological and market expertise of its people. It is this unique position that enables the Lonza team to push the boundaries of pharmaceutical development and manufacturing, and serve as a partner of choice for the global biopharma industry in its quest to turn breakthrough innovations into viable therapies. Together, we will enable a healthier world for patients in need.”

Note to editors: 
A high-resolution image of Wolfgang is available on request from [e-mail]
 

About Lonza

Lonza is one of the world’s largest healthcare manufacturing organizations. Working across five continents, our global community of around 18,000 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments to market. United by our vision to bring any therapy to life, we support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments.